Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics

Abstract Glioblastoma (GBM) is the most aggressive malignant brain tumour, with a median survival of 3 months without treatment and 15 months with treatment. Early GBM diagnosis can significantly improve patient survival due to early treatment and management procedures. Magnetic resonance imaging (MRI) using contrast agents is the preferred method for the preoperative detection of GBM tumours. However, commercially available clinical contrast agents do not accurately distinguish between GBM, surrounding normal tissue, and other cancer types due to their limited ability to cross the blood-brain barrier (BBB), their low relaxivity, and their potential toxicity. New GBM-specific contrast agents are urgently needed to overcome the limitations of current contrast agents. Recent advances in nanotechnology have produced alternative GBM-targeting contrast agents. The surfaces of nanoparticles (NPs) can be modified with multimodal contrast imaging agents and ligands that can specifically enhance the accumulation of NPs at GBM sites. Using advanced imaging technology, multimodal NP-based contrast agents have been used to obtain accurate GBM diagnoses in addition to an increased amount of clinical diagnostic information. NPs can also serve as drug delivery systems for GBM treatments. This review focuses on the research progress for GBM-targeting MRI contrast agents as well as MRI-guided GBM therapy.

Download Full-text

Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells

Journal of Materials Chemistry B ◽

10.1039/d1tb01147b ◽

2021 ◽

Author(s):

Anton Popov ◽

Maxim Artemovich Abakumov ◽

Irina Savintseva ◽

Artem Ermakov ◽

Nelly Popova ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Contrast Agents ◽

Mri Contrast Agents ◽

Cerium Oxide Nanoparticles ◽

Oxide Nanoparticles ◽

Resonance Imaging ◽

Mri Contrast ◽

Selective Cytotoxicity ◽

Magnetic Resonance Imaging Mri

Gd-based complexes are widely used as magnetic resonance imaging (MRI) contrast agents. The safety of previously approved contrast agents is questionable and is being re-assessed. The main causes of concern...

Download Full-text

Pushing the Sensitivity Envelope of Lanthanide-Based Magnetic Resonance Imaging (MRI) Contrast Agents for Molecular Imaging Applications

Accounts of Chemical Research ◽

10.1021/ar800192p ◽

2009 ◽

Vol 42 (7) ◽

pp. 822-831 ◽

Cited By ~ 279

Author(s):

Silvio Aime ◽

Daniela Delli Castelli ◽

Simonetta Geninatti Crich ◽

Eliana Gianolio ◽

Enzo Terreno

Keyword(s):

Magnetic Resonance Imaging ◽

Molecular Imaging ◽

Magnetic Resonance ◽

Contrast Agents ◽

Mri Contrast Agents ◽

Resonance Imaging ◽

Mri Contrast ◽

Magnetic Resonance Imaging Mri

Download Full-text

Effect of Gd and Dy Concentrations in Layered Double Hydroxides on Contrast in Magnetic Resonance Imaging

Processes ◽

10.3390/pr8040462 ◽

2020 ◽

Vol 8 (4) ◽

pp. 462 ◽

Cited By ~ 1

Author(s):

Karina Nava Andrade ◽

Gregorio Guadalupe Carbajal Arízaga ◽

José Antonio Rivera Mayorga

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Contrast Agents ◽

Mri Contrast Agents ◽

Resonance Imaging ◽

Mri Contrast ◽

Molar Ratios ◽

Magnetic Resonance Imaging Mri ◽

Double Hydroxide ◽

Double Hydroxides

In this work, we explore the synthesis of layered double hydroxide (LDH) particles containing different molar ratios of Gd3+ and Dy3+ cations. A single crystalline phase was obtained for Zn2.0Al0.75Gd0.125Dy0.125-LDH and Zn2.0Al0.5Gd0.25Dy0.25-LDH, and their efficiency as contrast agents was evaluated by T1- and T2-weighted magnetic resonance imaging (MRI). Both GdDy-LDHs exhibited longitudinal relaxivity (r1) higher than a commercial reference. The highest contrast in the T1 mode was achieved with the Zn2.0Al0.75Gd0.125Dy0.125-LDH, which contained the lowest concentration of lanthanides; this efficiency is related to the lowest amount of carbonate anions complexing the lanthanide sites. On the contrary, the best contrast in the T2 mode was achieved with Zn2.0Al0.5Gd0.25Dy0.25-LDH. Zn2.0Al0.75Gd0.125Dy0.125-LDH and Zn2.0Al0.5Gd0.25Dy0.25-LDH presented r2/r1 ratios of 7.9 and 22.5, respectively, indicating that the inclusion of gadolinium and dysprosium into layered structures is a promising approach to the development of efficient bimodal (T1/T2) MRI contrast agents.

Download Full-text

Ferritin: A Platform for MRI Contrast Agents Delivery

Inorganics ◽

10.3390/inorganics7030033 ◽

2019 ◽

Vol 7 (3) ◽

pp. 33 ◽

Cited By ~ 3

Author(s):

Maria Ruggiero ◽

Diego Alberti ◽

Valeria Bitonto ◽

Simonetta Geninatti Crich

Keyword(s):

Magnetic Resonance Imaging ◽

Targeted Therapy ◽

Magnetic Resonance ◽

Contrast Agents ◽

Mri Contrast Agents ◽

Resonance Imaging ◽

Mri Contrast ◽

Magnetic Resonance Imaging Mri ◽

Accurate Imaging ◽

Unique Surface

The search for high relaxivities and increased specificity continues to be central to the development of paramagnetic contrast agents for magnetic resonance imaging (MRI). Ferritin, due to its unique surface properties, architecture, and biocompatibility, has emerged as a natural nanocage that can potentially help to reach both these goals. This review aims to highlight recent advances in the use of ferritin as a nanoplatform for the delivery of metal-based MRI contrast agents (containing Gd3+, Mn2+, or Fe2O3) alone or in combination with active molecules used for therapeutic purposes. The collected results unequivocally show that the use of ferritin for contrast agent delivery leads to more accurate imaging of cancer cells and a significantly improved targeted therapy.

Download Full-text

Uniform Fe3O4/Gd2O3-DHCA nanocubes for dual-mode magnetic resonance imaging

Beilstein Journal of Nanotechnology ◽

10.3762/bjnano.11.84 ◽

2020 ◽

Vol 11 ◽

pp. 1000-1009

Author(s):

Miao Qin ◽

Yueyou Peng ◽

Mengjie Xu ◽

Hui Yan ◽

Yizhu Cheng ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Contrast Agents ◽

Mri Contrast Agents ◽

Clinical Diagnostics ◽

Resonance Imaging ◽

Dual Mode ◽

Mri Contrast ◽

Magnetic Resonance Imaging Mri

The multimodal magnetic resonance imaging (MRI) technique has been extensively studied over the past few years since it offers complementary information that can increase diagnostic accuracy. Simple methods to synthesize contrast agents are necessary for the development of multimodal MRI. Herein, uniformly distributed Fe3O4/Gd2O3 nanocubes for T 1–T 2 dual-mode MRI contrast agents were successfully designed and synthesized. In order to increase hydrophilicity and biocompatibility, the nanocubes were coated with nontoxic 3,4-dihydroxyhydrocinnamic acid (DHCA). The results show that iron (Fe) and gadolinium (Gd) were homogeneously distributed throughout the Fe3O4/Gd2O3-DHCA (FGDA) nanocubes. Relaxation time analysis was performed on the images obtained from the 3.0 T scanner. The results demonstrated that r 1 and r 2 maximum values were 67.57 ± 6.2 and 24.2 ± 1.46 mM−1·s−1, respectively. In vivo T 1- and T 2-weighted images showed that FGDA nanocubes act as a dual-mode contrast agent enhancing MRI quality. Overall, these experimental results suggest that the FGDA nanocubes are interesting tools that can be used to increase MRI quality, enabling accurate clinical diagnostics.

Download Full-text